Ming Lu

发表

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

S. Liao, Honghui Zhou, N. Yeilding, 2009, Journal of clinical pharmacology.

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

E. Liu, H. Brashear, M. Delnomdedieu, 2016, Alzheimer's Research & Therapy.

Population‐Based Exposure‐Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

S. Liao, Honghui Zhou, N. Yeilding, 2010, Journal of clinical pharmacology.

Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study.

S. Salloway, G. Marshall, H. Brashear, 2018, Current Alzheimer research.

Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

Kaori Ito, Chuanpu Hu, S. Raje, 2015, Journal of clinical pharmacology.

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

E. Liu, H. Brashear, M. Delnomdedieu, 2016, Alzheimer's Research & Therapy.

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.

E. Liu, G. Novak, J. Werth, 2016, Journal of Alzheimer's disease : JAD.

Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.

E. Liu, Kaori Ito, B. Corrigan, 2016, Journal of Alzheimer's disease : JAD.

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab

Kaori Ito, B. Corrigan, H. Brashear, 2015, Alzheimer's & dementia.

Association of GBA genotype with motor and cognitive decline in Chinese Parkinson’s disease patients

Jingru Ren, Yu Sun, Changyan Ma, 2023, Frontiers in Aging Neuroscience.

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single‐Ascending‐Dose Study in Patients With Mild to Moderate Alzheimer Disease

H. Brashear, Ming Lu, 2018, Clinical pharmacology in drug development.

Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials

Kaori Ito, B. Corrigan, H. Brashear, 2015, Alzheimer's & dementia.